Yuhan Corporation acquires ‘Sovaldi’ & ‘Harvoni’ license worth of KRW 120 billion a year
In the official notice on the 5th, Yuhan Corporation announced it signed an exclusive sales agreement of ‘Sovaldi’ and ‘Harvoni,’ hepatitis C treatments, in Korea with U.S. Gilead.
Gilead’s ‘Sovaldi’ and ‘Harvoni’ sales in Korea were approximately KRW 120 billion in 2016.
Yuhan Corporation expl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
